Bortezomib Retreatment in Relapsed Multiple Myeloma – Results from a Retrospective Multicentre Survey in Germany and Switzerland
Authors:
Open Access
- 1 January 2010
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 79 (3-4) , 247-254
Abstract
Objectives: This multicenter, retrospective survey evaluated the efficacy and safety of bortezomib retreatment in patients with relapsed multiple myeloma who had responded to initial bortezomib treatment. Methods: Clinical records of 94 patients receiving bortezomib retreatment in Germany and Switzerland were reviewed. Results: Sixty patients were included according to prespecified criteria. Patients had received a mean 3.7 ± 2.3 therapies prior to initial bortezomib. Overall response rate to bortezomib retreatment was 63.3%; 8 (13.3%), 3 (5.0%) and 27 (45.0%) patients achieved complete response (CR), near-CR and partial response, respectively. Response to retreatment was associated with response to initial treatment (75.0% of patients with CR to initial treatment responded to retreatment) and treatment-free interval (TFI) after initial treatment (76.9 vs. 38.1% overall response rate for patients with TFI >6 vs. ≤6 months). After retreatment, median time to progression was 9.3 months. Median TFI was 5.7 months; 31.7, 25.0 and 15.0% of patients experienced a TFI longer than 6, 9 and 12 months, respectively. Reported adverse drug reactions were consistent with the known safety profile of bortezomib and most resolved completely. Conclusions: These results demonstrate that relapsed multiple myeloma patients who respond to initial bortezomib treatment have a sustained susceptibility to bortezomib and do not experience uncommon toxicity to retreatment.Keywords
This publication has 12 references indexed in Scilit:
- Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA TrialJournal of Clinical Oncology, 2010
- Efficacy and Safety of Retreatment with Bortezomib in Patients with Multiple Myeloma: Interim Results From RETRIEVE, a Prospective International Phase 2 Study.Blood, 2009
- Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guidelineBritish Journal of Haematology, 2009
- Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaBritish Journal of Haematology, 2008
- An Observational, Retrospective Analysis of Retreatment with Bortezomib for Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2008
- Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialBlood, 2007
- Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With BortezomibJournal of Clinical Oncology, 2006
- Hematologic Profiles in the Phase 3 APEX Trial.Blood, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Clinical Course of Patients With Relapsed Multiple MyelomaMayo Clinic Proceedings, 2004